Energenesis Biomedical is pioneering in powering cells and translating this unique concept into therapeutics for certain diseases. New drugs under clinical development by the company include ENERGI-F703 (gel for diabetes foot ulcer) and ENERGI-F701 (solution for treating alopecia). Both have completed phase II trials in Taiwan, following the approvals of the same by the U.S. FDA. The EPO2 meeting with the U.S. FDA for ENERGI-F703 has been completed. The phase 3 study is under preparation and will be kicked off in 2022.

Backed by a solid R&D team, Energenesis Biomedical has close cooperation with academic and research institutes, which brings us a portfolio of new drugs and meanwhile agility in this dynamic world of biomedical research. Our mission is to develop new drugs with the ENERGI platform, with our features in elevating the quality of life and addressing unmet medical needs through novel approaches.

ENIMMUNE contributes to the development of vaccines and protein drugs. It focuses on potentially lethal Enterovirus 71 vaccines. Otherwise, the hand-foot-and-mouth disease caused by Coxsackie virus is another subtropical epidemic virus, and ENIMMUNE's objective is to research the EV71+CA16 bivalent vaccine. ENIMMUNE's major products aim to develop the Japanese Encephalitis vaccine using serum-free cell culture technology and bioreactor system, the Pneumococcal vaccine, and the Tetanus Toxoid vaccine.

Established in Dec 2016, Ever Supreme Bio Technology(Ever Supreme) targets the cell therapy market for unmet medical needs. Through obtaining exclusive technology licenses from Academia Sinica, National Chiao Tung University and China Medical University(Taiwan), Ever Supreme conducts R&D of immune cell therapy and stem cell drugs, and develops the cell therapy for critical illnesses, providing new hopes for critical illness treatment along with personalized cell therapy in response to individual differences.

EXCELSIOR BIOPHARMA INC., founded in Taipei City, Taiwan in 1986, has developed the service for agency, import and distribution of medicines for more than three decades in order to provide enterprises in Taiwan and Asian market with excellent medical services. In order to realize the vision for prolonging human life, we focus on the healthcare service for special diseases in Taiwan and Asia, and provide services to the minority of patients with diseases in urgent need of medical treatment in the market.

In 2021, the Company added the medicine permits of the medicines for two rare disorders, which the patients rely on to survive. The Company also continues to invest funds in the development of the market for health supplements and provide precise health supplements in Taiwan.

Fecula Biotech Co., Ltd. was established in February 2019. The headquarter is located in SME Incubator Center, Southern Taiwan Science Park. In 2020, it was received funding from the National Development Fund Startup Angel Project. In 2022, it was listed on TPEx Go Incubation Board for Startups and Acceleration Firms (GISA) with the stock code 7627, having a paid-in capital of NTD 35 million.

Our mission is to develop innovative and efficient approaches to address the growing agricultural waste issues transforming them into eco-efficient, sustainable product opportunities that directly benefit the environment, economy, and consumers. We have already succussed in converting agro-waste, such as banana, Citrus depressa Hayata, strawberry leaves, and fish scales, into functional food ingredients and supplement products. Furthermore, the strawberry leaf extract has been successfully developed as a cosmetics ingredient, and clinical studies have indicated that it exhibits visible improvements in skin brightness, moisture, and elasticity.

Our core technology is the Resistant Starch-Based Encapsulation Technique (RS-BET) which utilizes banana resistant starch as building block. This innovative approach can be applied to the development of pharmaceuticals and supplements, depending on the specific specifications of the resistant starch. Through the synergistic combination of probiotics and new agricultural resources, we have successfully launched microbiota-related (probiotic) dietary supplements, which have gained a market presence worldwide. Currently, our supplement products are available in the United States and Mainland China through e-commerce channels, in Vietnam through TV shopping, and in Taiwan through e-commerce and pharmacy chain stores of Great Tree Pharmacy Co., Ltd.

In addition to our current achievements, we are actively involved in the development of microbiome-based therapeutics and vaccines, utilizing the core technology of RS-BET. Our pipeline includes the following projects: (1) Oral delivery of HCC vaccine; (2) oral FMT capsule for cancer adjuvant therapy; (3) Botanical drug for the inhibition of cancer invasion and metastasis.

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee’s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting disease areas with high unmet needs.

Foresee's product portfolio includes late stage and early stage programs.
1) FP-001 – stable, ready-to-use versions of leuprolide mesylate for injection, for which regulatory approval reviews are currently underway in US and EU for the 6-month product and regulatory submissions for 3-month product are in preparation.
2) FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS).
3) FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
4) FP-004 – a novel, subcutaneously injectable product in development for the treatment of opioid use disorder and pain.

Genomics BioSci & Tech Co., Ltd is dedicated to advancing precision medicine through innovative molecular diagnostics and genomic technologies. By integrating next-generation sequencing (NGS), molecular testing, and bioinformatics analysis, we deliver practical and reliable solutions for clinical applications and health management.

Our services support disease risk assessment, therapeutic decision-making, and preventive healthcare, transforming complex genomic data into actionable insights.

We place strong emphasis on testing quality, process transparency, and data security, ensuring trust at every stage. Through close collaboration with medical institutions, academic organizations, and industry partners, Genomics BioSci & Tech Co., Lid aims to accelerate the real-world adoption of precision medicine and contribute to more informed medical decisions and improved public health outcomes.

Great Novel Therapeutics Biotech and Medicals Corporation , (GNTbm) is a Taiwanese biotech new drug company. GNTbm focuses on the development of innovative drugs, mainly for the treatment of advanced and refractory can cers. In addition to the licensed in new drug Tucidinostat, two indications have been completed in Taiwan. The independent developed new drug combination of tumor microenvironment regulators is being conducted in clinical trials for proof of concept. The independent development of a new generation of oral epigenetic immunomodulator with international competitive advantages, GNTbm-38. GNTbm-38, which is undergoing preclinical study, has the potential to become a best in class for next-generation cancer immunotherapy. GNTbm is interested in the development of innovative drugs in the new generation of cancer immunotherapy, hoping to selectively attack tumors and obtain long -term immune memory by activating the host's immune system, so that advanced cancer patients can get more lasting effects and avoid cancer recurrence. On the other hand, GNTbm has cooperated with international pharmaceutical companies to introduce the global OEM demand for new anti-cancer drugs to Taiwan to supply the needs of advanced cancer patients around the world.

In the future , Regenerative medicine and cell therapy will be the most importment medical technology in the world . Regenerative medicine and cell medicine are areas of considerable potential growth. Cell medicine is a state-of-the-art technology that provides treatment using patients' own (or other people's) cells. The field of cell medicine can broadly be divided into two areas: regenerative medicine that aims to re-grow body parts such as cultured skin or cartilage, and cell transplant medicine that treats cancer or congenital diseases. GUANG-LI biomedicine lns. is the first company to provide adult stem cell banking in Taiwan. Our distinguished team includes internationally renowed experts in the fields of stem cell biology,biotechnology, regenerative medicine,and GTP manufacturing. Everybody's own stem cells are unique and precious, Guang Li's mission is to develop the leading technology and to manufacture the best-in-class stem cells to meet our clients' requirement at all tímes.